Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD).

Locations

14 United States sites

5 Kenya sites

4 Turkey sites

3 France sites

3 Italy sites

2 Brazil sites

2 Lebanon sites

1 Germany site

1 Saudi Arabia site

1 Oman site

1 Tanzania site

1 United Kingdom site

Age

12 Years to Years

Genotypes

3

Phase

Phase 3

LEARN MORE
An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.

Locations

3 United States sites

3 Brazil sites

3 Turkey sites

2 Belgium sites

2 Italy sites

2 Lebanon sites

1 Colombia site

1 France site

1 Oman site

1 Germany site

1 Spain site

Age

6 Months to Years

Phase

Phase 4

LEARN MORE
ESCORT-HU Extension: European Sickle Cell Disease Cohort – Hydroxyurea – Extension

As safety information pertaining to the long-term use of HU remains incomplete in spite of the first safety study (ESCORT-HU), an extension of the latter is proposed.

Locations

61 France site

5 Germany sites

4 French Guiana sites

4 Italy sites

2 Guadeloupe sites

2 Martinique sites

1 Greece site

Age

2 Years to Years

LEARN MORE
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).

Locations

42 United States sites

4 France sites

4 Spain sites

2 Canada sites

2 Germany sites

2 Italy sites

1 United Kingdom site

Age

12 Years to 65 Years Years

Phase

Phase 2/Phase 3

LEARN MORE
A Phase II Stratified Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With Sickle Cell Disease With no Available Sibling Donor

HSCT is currently the only curative option for SCD but less than 20% of SCD patients have a MD donor available.

Locations

5 Germany sites

Age

1 Year to 35 Years Years

Phase

Phase 2

LEARN MORE
A Phase II Stratified Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With Sickle Cell Disease With no Available Sibling Donor

HSCT is currently the only curative option for SCD but less than 20% of SCD patients have a MD donor available.

Locations

5 Germany sites

Age

1 Year to 35 Years Years

Phase

Phase 2

LEARN MORE
A Phase II Stratified Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With Sickle Cell Disease With no Available Sibling Donor

HSCT is currently the only curative option for SCD but less than 20% of SCD patients have a MD donor available.

Locations

8 Germany sites

1 Austria site

Age

1 Year to 35 Years Years

Phase

Phase 2

LEARN MORE
Register Sichelzellkrankheit Der GPOH

Sickle cell disease is one of the most common hereditary diseases.

Locations

1 Germany site

Age

to 100 Years Years

Genotypes

2

LEARN MORE